ClinicalTrials.gg
RecruitingNCT07325136Updated Sep 14, 2026

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

A Phase 1/2 interventional study of BMS-986525 and Pumitamig in Relapsed/Refractory Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Recruiting at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.

Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
240
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb — 2 open to participants now, 2 under way, 1 of them phase 3. Small Cell Lung Carcinoma · Bristol-Myers Squibb.

Planned enrollment
5th of 17
240 · median 92
Started
2026
the only one that year
Phase 1/2
2 of 19
1 open now
Registered
19th of 19
by date

Among the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, this one is the 5th largest by planned enrollment of the 17 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 1/2, and was the 19th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Small Cell Lung Carcinoma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer

03

Conditions studied

  • Relapsed/Refractory Small Cell Lung Cancer

Keywords

  • Extensive stage-small cell lung cancer (ES-SCLC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have or cytologically documented small cell lung cancer (R/R-SCLC).
  • Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
  • In countries where standard of care systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L)1 therapy.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any untreated .
  • Participants must not have an active, known or suspected disease.
  • Participants must not have had a prior organ or tissue allograft.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Part 1A: BMS-986525 Monotherapy Dose Escalation

    Drug: BMS-986525

  • Experimental
    Part 2A: BMS-986525 Monotherapy Dose Expansion

    Drug: BMS-986525

  • Experimental
    Part 1B: BMS-986525 Combination with Pumitamig Dose Escalation

    Drug: BMS-986525 · Drug: Pumitamig

  • Experimental
    Part 2B: BMS-986525 Combination with Pumitamig Dose Expansion

    Drug: BMS-986525 · Drug: Pumitamig

Interventions

  • DrugBMS-986525

    Specified dose on specified days

  • Specified dose on specified days

    Also known as: BNT-327, BMS-986545

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    Time frame: Up to approximately 2 years

  2. Number of participants with serious adverse events (SAEs)

    Time frame: Up to approximately 2 years

  3. Number of participants with AEs meeting dose-limiting toxicity (DLT) criteria

    Time frame: Up to 21 days

  4. Number of participants with AEs leading to discontinuation

    Time frame: Up to approximately 2 years

  5. Number of participants with AEs leading to death

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumor Version 1.1 (RECIST v1.1) by investigator assessment

    Time frame: Up to approximately 3 years

  2. Maximum observed concentration within a dosing interval (Cmax)

    Time frame: Up to approximately 2 years

  3. Time of maximum observed plasma concentration within a dosing interval (Tmax)

    Time frame: Up to approximately 2 years

  4. Area under the concentration-time curve within a dosing interval (AUC(TAU))

    Time frame: Up to approximately 2 years

07

Study locations

10 of 13 sites recruiting
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
    Recruiting
    • Hirva Mamdani, Site 0011 · Contact313-576-8711
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
    Recruiting
    • Prantesh Jain, Site 0026 · Contact716-845-3099
  • Duke Cancer Institute
    Durham, North Carolina 27710, United States
    Recruiting
    • Neal Ready, Site 0005 · Contact919-681-7460
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
    Recruiting
    • Afshin Dowlati, Site 0004 · Contact216-844-5432
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Melissa Johnson, Site 0006 · Contact615-329-7274
  • Local Institution - 0029
    Beijing, Beijing Municipality 100036, China
    Not yet recruiting
    • Site 0029 · Contact
  • Shanghai East Hospital
    Shanghai, Shanghai Municipality 200120, China
    Recruiting
    • Caicun Zhou, Site 0028 · Contact8613301825532
  • Istituto Clinico Humanitas
    Rozzano, Milano 20089, Italy
    Recruiting
    • Matteo Simonelli, Site 0001 · Contact+390282244559
  • Local Institution - 0020
    Hirakata, Osaka 573-1191, Japan
    Not yet recruiting
    • Site 0020 · Contact
  • Local Institution - 0018
    Chuo-ku, Tokyo 104-0045, Japan
    Not yet recruiting
    • Site 0018 · Contact
  • Oncohelp Medical Center
    Timișoara, Timiș County 300239, Romania
    Recruiting
    • Cristina Oprean, Site 0023 · Contact+40745148485
  • Centrul de Oncologie Sf. Nectarie SRL
    Craiova, 200347, Romania
    Recruiting
    • Michael Schenker, Site 0003 · Contact40727774974
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • Luis Paz-Ares Rodriguez, Site 0009 · Contact0034913908922
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Apr 2029, 38 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 38 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 8, 2026
StartActual
Feb 3, 2026
Primary completionEst.
Apr 23, 2029
CompletionEst.
Apr 24, 2029
Last update
Sep 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07325136
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Feb 3, 2026
Primary completion
Apr 23, 2029 (estimated)
Completion
Apr 24, 2029 (estimated)
Last update
Sep 14, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion